Structure-Based Drug Design, Identification and Characterization

In the structure-based drug design (SBDD) approach, the 3D structure of a ligand bound to its biological target is determined with the ultimate goal to identify suitable small molecule ligands. The use of X-ray crystallography and molecular modeling can dramatically accelerate the process of optimizing early lead compounds, transforming them from leads with weak activities into highly potent, and selective, clinical candidates. Whenever possible, our team of expert chemists incorporate these technologies into our drug discovery collaborations.

Specific services include:

• Production and purification of target proteins
• X-ray crystallography of small molecule inhibitors bound to protein targets
• Molecular modeling for lead optimization
• Biophysical analysis of protein-inhibitor interactions to evaluate binding modes (thermodynamic and kinetic analysis)

FAQ

• What is Structure-Based Drug Design (SBDD)?

  SBDD utilizes the 3D structure of a target protein to design and identify molecules that specifically bind to it.

• What are the advantages of SBDD?

  SBDD can lead to the identification of more potent and selective drug candidates with a higher likelihood of success.

• Do you offer expertise in X-ray crystallography or other structural biology techniques?

  We offer protein production and crystallization services for X-ray crystallography, or have alternative methods for obtaining structural information for SBDD projects.

Learn more about